Drug Discovery World

JULY 2, 2024

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM).

Virus 147

Virus Trials Clinical Trials Laboratories 147

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Discovery World

MAY 20, 2024

BenevolentAI’s strategic collaboration with AstraZeneca began in 2019, and originally focused on discovering potential new treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). Current heart failure treatments follow a “one-size-fits-all” approach.

Disease 147

Disease Therapies Treatment Marketing 147

The Pharma Data

DECEMBER 11, 2020

11, 2020 — From 1990 to 2019, there was an increase in the burden of cardiovascular disease (CVD) globally, according to a study published online Dec. The researchers found that prevalent cases of total CVD increased from 271 million in 1990 to 523 million in 2019, and the number of CVD deaths increased from 12.1

Disease 52

Disease Pharmaceuticals Treatment Research 52

Drug Discovery World

SEPTEMBER 11, 2024

The trial also tested the safety profile of the treatment. A breakthrough in LCA1 The Boyes founded Atsena Therapeutics in 2019 to bring the LCA1 treatment and other gene therapies to market. The study enrolled 15 subjects who received the treatment in one eye, which involved a surgical injection in the retina.

Therapies 173

Therapies Trials Clinical Trials Laboratories 173

Drug Discovery World

OCTOBER 16, 2023

University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer’s Research UK UCL Drug Discovery Institute (UCL DDI).

Disease 130

Disease Treatment Regulations Science 130

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Drug Discovery World

JULY 19, 2024

She then moved into rare diseases and has been working on rare hepatic diseases for the last two decades, with a focus on the development of advanced therapies. Since 2014, Dr Gonzalez-Aseguinolaza has been head of the Gene Therapy Program at the Centro Investigación Médica Aplicada (CIMA), Universidad de Navarra, in Spain.

Therapies 130

Therapies Research Clinical Trials Science 130

The Pharma Data

DECEMBER 22, 2020

22, 2020 — Before the COVID-19 pandemic hit, life expectancy in the United States rose in 2019 for the second year in a row, according to two new federal government reports. That would be a new record and represent 400,000 more deaths than were recorded for 2019. Centers for Disease Control and Prevention. TUESDAY, Dec.

Disease 52

Disease Government Treatment Drugs 52

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . adults have been diagnosed with dry eye disease, a chronic, episodic, multifactorial disease. It also increases your risk for inflamed cornea, cornea eye disease, corneal ulcers and injuries, and eye infections. .

FDA 52

FDA Disease Treatment FDA Approval 52

Drug Discovery World

JANUARY 2, 2024

South Korean researchers have found that the use of Janus kinase (JAK) inhibitors as a treatment for atopic dermatitis (AD) is not associated with a greater risk of serious adverse events. They reviewed the available safety data and analysed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

FDA 130

FDA Treatment Disease Trials 130

Creative Biolabs

JANUARY 15, 2020

By understanding the mechanism of new product development, product screening and production processes, as well as the diseases and symptoms that drugs need to treat, CDER provides scientific and regulatory advices for products that are about to be brought to market.

Clinical Trials 52

Clinical Trials FDA Trials Drugs 52

Broad Institute

JULY 10, 2024

A three-drug cocktail known as Trikafta has greatly improved patient quality of life since its development in 2019, but can cause cataracts and liver damage and must be taken daily at a cost of about $300,000 per year. With further development, it could pave the way for treatments that are administered only once and have fewer side effects.

Engineering 145

Engineering Packaging DNA Treatment 145

Drug Discovery World

NOVEMBER 13, 2023

Genome sequencing has been used to study typhoid fever in a study in Zimbabwe and understand how the disease has evolved to be resistant to treatment. In response, an emergency reactive vaccination campaign using Typhoid Conjugate Vaccine (TCV) was initiated in suburbs of Harare in 2019, providing moderate protection.

Vaccine 130

Vaccine International Treatment Disease 130

BioPharma Drive: Drug Pricing

AUGUST 28, 2023

The treatment, developed by a biotech Bayer acquired in 2019, appeared safe in a small trial and showed signs of an effect on disease progression.

Therapies 98

Therapies Trials Treatment Disease 98

Drug Discovery World

JULY 15, 2022

Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).? . Asthma is thought to affect over 300 million people and in 2019 caused 455,000 deaths 1. Official comments .

Pharmaceutical Companies 130

Pharmaceutical Companies Therapies Production Treatment 130

Drug Discovery World

NOVEMBER 1, 2022

Its snapshot report aimed to provide both an overview of the sector in Australia to determine how the sector has changed since this data was collected in 2017 and 2019 2. . The number of employees behind our biotech companies has also expanded, increasing 21% compared with 2019 from approximately 87,397 people in 2019 to 105,569 in 2022.

Drugs 130

Drugs Science Therapies Clinical Trials 130

Common Sense for Drug Policy Blog

AUGUST 26, 2024

Health Consequences of Alcohol Consumption "• The global burden of disease and injuries caused by alcohol consumption can be quantified for 31 health conditions on the basis of the available scientific evidence for the role of alcohol use in their development, occurrence and outcomes. "• Worldwide, 2.6 of all DALYs among males and 0.6

Disease 52

Disease Treatment 52

Drug Discovery World

SEPTEMBER 22, 2022

Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. CytoReason’s platform has reportedly provided Pfizer with insights in research and development programs across over 20 diseases. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Licensing Licensing 130

Drug Discovery World

NOVEMBER 9, 2022

Patients can now access SZC in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care. . SZC is already used within NHS Scotland for hyperkalaemia as outpatient care for adults with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure. .

Treatment 130

Treatment Disease Drugs 130

Drug Discovery World

JANUARY 19, 2023

A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint. million related deaths globally. “The trial shows promising positive results across a variety of primary and secondary endpoints.

Drugs 130

Drugs Clinical Trials Trials Virus 130

Drug Discovery World

FEBRUARY 12, 2024

It’s not even clear whether patients and their families will notice any benefit from the treatment, and there are serious questions about its value for women (women are twice as likely as men to develop Alzheimer’s). After all, these failures come on top of decades and decades of research into these diseases.

Animal Testing 147

Animal Testing Disease Trials Research 147

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Drug Discovery World

SEPTEMBER 27, 2023

The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable. Seven years of trial data DLd is licensed and has been available for use in Europe since 2019.

Regulations 130

Regulations Licensing Licensing Therapies 130

Drug Discovery World

JANUARY 29, 2024

How phages work still a mystery In 2019, the team isolated a new, previously unknown virus that infects Pseudomonas aeruginosa, a bacterium that can cause serious respiratory diseases like pneumonia. However, you need to know exactly how a phage attacks a bacterium before you can select the right phages for a particular treatment.

Virus 130

Virus Hospitals Treatment Research 130

Drug Discovery World

JANUARY 8, 2024

Importantly, regulatory guidelines facilitate this, allowing us to use highly translatable animal model data to complement leaner clinical trials in support of registration,” said Michael Lobritz, Head of Infectious Diseases, Roche Pharma Research and Early Development (pRED). Government incentives provide one solution.

Clinical Trials 130

Clinical Trials Government Drugs Trials 130

Chemical Biology and Drug Design

OCTOBER 5, 2023

Abstract Sickle cell disease (SCD) is the most common genetic disorder, affecting millions of people worldwide. However, the aldehyde functional group metabolic instability has severly hampered their development, except for voxelotor, which was approved in 2019 for SCD treatment.

Metabolic Stability 100

Metabolic Stability Treatment Disease Research 100

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Olympus announced that Highmark Blue Cross Blue Shield (BCBS) updated its coverage policy to include the Spiration ® Valve System for eligible patients suffering from severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). . CENTER VALLEY, Pa. , ” . ” .

Treatment 52

Treatment Clinical Trials Trials Disease 52

Drug Discovery World

OCTOBER 18, 2023

Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas. We’re beginning to see their potential come to fruition, with the FDA having approved three treatments as of January 2023 — for retinal dystrophy 1 spinal muscular atrophy, 2 and haemophilia B.

Therapies 162

Therapies Clinical Trials FDA Approval Virus 162

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. Based on these data, ADT alone should no longer be considered sufficient for patients with advanced, castration-sensitive disease.”.

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. In my case, my daughter Iris has GM1 gangliosidosis.

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

BioPharma Drive: Drug Pricing

AUGUST 18, 2023

The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma.

Treatment 52

Treatment Disease Drugs 52

The Pharma Data

AUGUST 19, 2020

(Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 Nipocalimab recently received a rare pediatric disease designation from the U.S. Food and Drug Administration. An estimated 2.5

Disease 52

Disease Pharmaceuticals Treatment Pharmaceutical Companies 52

Drug Discovery World

JANUARY 13, 2023

The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases. .

Small Molecule 130

Small Molecule Treatment Disease Research 130